Background Reports suggest that COVID-19 vaccine effectiveness is decreasing, but whether
this reflects waning or new SARS-CoV-2 variants—especially delta (B.1.617.2)—is unclear…

There is considerable interest in the waning of effectiveness of coronavirus disease 2019 (COVID-19)
vaccines and vaccine effectiveness (VE) of booster doses. Using linked national …

Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) promotes
challenging immune and inflammatory phenomena. Though various therapeutic possibilities …

Background Aging influences COVID-19 severity and response to vaccination, but previous
vaccine effectiveness (VE) analyzes lack the power to evaluate its role in subgroups within …

Although severe COVID-19 in children is rare, they may develop multisystem inflammatory
syndrome, long-COVID and downstream effects of COVID-19, including social isolation and …

As of May 11, 2022, an estimated 519 million individuals have been infected with SARS-CoV-2,
and at least 11 billion COVID-19 vaccine doses were positive and defined as cases, and …

Background Little is known about vaccine effectiveness over time among adolescents,
especially against the SARS-CoV-2 omicron (B.1.1.529) variant. This study assessed the …

Background COVID-19 vaccines have proven highly effective among individuals without a
previous SARS-CoV-2 infection, but their effectiveness in preventing symptomatic infection …

To date, no information has been published on the effectiveness of inactivated whole-virus
COVID-19 vaccines plus heterologous booster against symptomatic infection and severe …

Background There is limited data on the prevalence and risk factors for long COVID and few
prospective studies with appropriate control groups and adequate sample sizes. We …